126 related articles for article (PubMed ID: 35809536)
21. Corrigendum to "Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview" [Eur. J. Med. Chem. 194 (2020) 112260].
Mondal S; Adhikari N; Banerjee S; Amin SA; Jha T
Eur J Med Chem; 2020 Nov; 205():112642. PubMed ID: 32750565
[No Abstract] [Full Text] [Related]
22. Corrigendum to "Design, synthesis and evaluation of hybrid of tetrahydrocarbazole with 2,4-diaminopyrimidine scaffold as antibacterial agents" [Eur. J. Med. Chem. 162 (162) (2019) 203-211].
Su L; Li J; Zhou Z; Huang D; Zhang Y; Pei H; Guo W; Wu H; Wang X; Liu M; Yang CG; Chen Y
Eur J Med Chem; 2019 Apr; 168():385. PubMed ID: 30826513
[No Abstract] [Full Text] [Related]
23. ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells.
Talekar MK; Allen JE; Dicker DT; El-Deiry WS
Cell Cycle; 2015 Aug; 14(15):2422-8. PubMed ID: 26030065
[TBL] [Abstract][Full Text] [Related]
24. Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis.
Borsuk R; Zhou L; Chang WI; Zhang Y; Sharma A; Prabhu VV; Tapinos N; Lulla RR; El-Deiry WS
Am J Cancer Res; 2021; 11(9):4607-4623. PubMed ID: 34659909
[TBL] [Abstract][Full Text] [Related]
25. Corrigendum to <'Synthesis and biological evaluation of 2,6-disubstituted-9H-purine, 2,4-disubstitued-thieno[3,2-d]pyrimidine and -7H-pyrrolo[2,3-d] pyrimidine analogues as novel CHK1 inhibitors' [Eur. J. Med. Chem. 151 (2018) 836-848].
Tian C; Han Z; Li Y; Wang M; Yang J; Wang X; Zhang Z; Liu J
Eur J Med Chem; 2019 Jul; 173():184. PubMed ID: 31003059
[No Abstract] [Full Text] [Related]
26. Corrigendum to "Design, synthesis, DFT study and antifungal activity of the derivatives of pyrazolecarboxamide containing thiazole or oxazole ring" [Eur. J. Med. Chem. 149 (2018) 170-181].
Yan Z; Liu A; Huang M; Liu M; Pei H; Huang L; Yi H; Liu W; Hu A
Eur J Med Chem; 2018 May; 152():392. PubMed ID: 29747120
[No Abstract] [Full Text] [Related]
27. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms.
Wagner J; Kline CL; Zhou L; Khazak V; El-Deiry WS
J Exp Clin Cancer Res; 2018 Jan; 37(1):11. PubMed ID: 29357916
[TBL] [Abstract][Full Text] [Related]
28. TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic.
Ralff MD; Jhaveri A; Ray JE; Zhou L; Lev A; Campbell KS; Dicker DT; Ross EA; El-Deiry WS
Oncotarget; 2020 Oct; 11(42):3753-3769. PubMed ID: 33144917
[TBL] [Abstract][Full Text] [Related]
29. Corrigendum to"Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo"[Eur. J. Med. Chem. 190 (2020 Mar 15) 112086].
Ojha R; Nepali K; Chen CH; Chuang KH; Wu TY; Lin TE; Hsu KC; Chao MW; Lai MJ; Lin MH; Huang HL; Chang CD; Pan SL; Chen MC; Liou JP
Eur J Med Chem; 2020 Sep; 201():112404. PubMed ID: 32526554
[No Abstract] [Full Text] [Related]
30. Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment.
Wagner J; Kline CL; Zhou L; Campbell KS; MacFarlane AW; Olszanski AJ; Cai KQ; Hensley HH; Ross EA; Ralff MD; Zloza A; Chesson CB; Newman JH; Kaufman H; Bertino J; Stein M; El-Deiry WS
J Clin Invest; 2018 Jun; 128(6):2325-2338. PubMed ID: 29533922
[TBL] [Abstract][Full Text] [Related]
31. Corrigendum to "Synthesis and evaluation of isoprenylation-resveratrol dimer derivatives against Alzheimer's disease" [Eur. J. Med. Chem. 163 (2019), 307-319. DOI: 10.1016/j.ejmech.2018.11.040].
Tang YW; Shi CJ; Yang HL; Cai P; Liu QH; Yang XL; Kong LY; Wang XB
Eur J Med Chem; 2024 Jun; ():116591. PubMed ID: 38890013
[No Abstract] [Full Text] [Related]
32. Corrigendum to "Optimization of physicochemical properties for 4-Anilinoquinazoline inhibitors of trypanosome proliferation" [Eur. J. Med. Chem. 141 (2017) 446-459].
Woodring JL; Bachovchin KA; Brady KG; Gallerstein MF; Erath J; Tanghe S; Leed SE; Rodriguez A; Mensa-Wilmot K; Sciotti RJ; Pollastri MP
Eur J Med Chem; 2018 May; 152():515. PubMed ID: 29754075
[No Abstract] [Full Text] [Related]
33. Corrigendum to "Synthesis of the pH-sensitive nanoparticles based on the acylhydrazone bonds conjugated doxorubicin and studies on their in vivo anti-tumor effects" [Eur. J. Med. Chem. 260 (2023) 115715].
Shi Y; Pan X; Xu S; Zhu H; Zhao B; Sun Z; Dong R; Li N; Hou X; Yang X
Eur J Med Chem; 2023 Dec; 262():115887. PubMed ID: 37867086
[No Abstract] [Full Text] [Related]
34. Corrigendum to <' Omipalisib inspired macrocycles as dual PI3K/mTOR inhibitors' [Eur. J. Med. Chem. 211 (2021), 113109].
Alvarez RM; García AB; Riesco-Fagundo C; Martín JI; Varela C; Rodríguez Hergueta A; González Cantalapiedra E; Oyarzabal J; Di Geronimo B; Lorenzo M; Albarrán MI; Cebriá A; Cebrián D; Martínez-González S; Blanco-Aparicio C; Pastor J
Eur J Med Chem; 2021 Nov; 224():113703. PubMed ID: 34284231
[No Abstract] [Full Text] [Related]
35. Corrigendum to "Pyridine and nitro-phenyl linked 1,3,4-thiadiazoles as MDR-TB inhibitors" [Eur. J. Med. Chem. 167 (2019) 1-9].
Patel H; Jadhav H; Ansari I; Pawara R; Surana S
Eur J Med Chem; 2020 Aug; 200():112413. PubMed ID: 32512481
[No Abstract] [Full Text] [Related]
36. Corrigendum to "Synthesis and cytotoxic activity of novel A-ring cleaved ursolic acid derivatives in human non-small cell lung cancer cells" [Eur. J. Med. Chem. 123 (2016) 317-331].
Mendes VIS; Bartholomeusz GA; Ayres M; Gandhi V; Salvador JAR
Eur J Med Chem; 2016 Nov; 124():1004-1005. PubMed ID: 27783971
[No Abstract] [Full Text] [Related]
37. Corrigendum to "New desulfured troglitazone derivatives: Improved synthesis and biological evaluation" [Eur. J. Med. Chem. 187 (2020) 111939].
Dupommier D; Muller C; Comoy C; Mazerbourg S; Bordessa A; Piquard E; Pawlak M; Piquard F; Martin H; De Fays E; Grandemange S; Flament S; Boisbrun M
Eur J Med Chem; 2020 Dec; 208():112834. PubMed ID: 32966897
[No Abstract] [Full Text] [Related]
38. Corrigendum to "Synthesis and preliminary antiproliferative activity of new pteridin-7(8H)-one derivatives" [Eur. J. Med. Chem. 143 (2018) 1396-1405].
Li ZH; Zhao TQ; Liu XQ; Zhao B; Wang C; Geng PF; Cao YQ; Fu DJ; Jiang LP; Yu B; Liu HM
Eur J Med Chem; 2019 Nov; 181():111387. PubMed ID: 31376565
[No Abstract] [Full Text] [Related]
39. Corrigendum to "From irreversible to reversible covalent inhibitors: Harnessing the andrographolide scaffold for anti-inflammatory action" [Eur. J. Med. Chem. 204 (2020) 112481].
Tran QTN; Tan DWS; Wong WSF; Chai CLL
Eur J Med Chem; 2021 Jan; 209():112943. PubMed ID: 33097302
[No Abstract] [Full Text] [Related]
40. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.
Allen JE; Krigsfeld G; Patel L; Mayes PA; Dicker DT; Wu GS; El-Deiry WS
Mol Cancer; 2015 May; 14():99. PubMed ID: 25927855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
